Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial

By N. Kiyota, M. Tahara, J. Mizusawa, T. Kodaira, H. Fujii, T. Yamazaki, H. Mitani, S. Iwae, Y. Fujimoto, Y. Onozawa and 23 more. 2022

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation (2023, background): “Furthermore, the data from clinical trials have shown that both of the aforementioned cisplatin regimens do not significantly differ in terms of patient outcome when combined with radiotherapy for primary or adjuvant treatment of locally advanced HNSCC [39,40].”
Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy (2025, unknown): “An alternative strategy currently being explored is the use of weekly high-dose cisplatin, which offer more frequent administration while maintaining efficacy [97,98].”